MiR-329-containing exosomes derived from breast tumor cells suppress VEGF and KDM1A expression in endothelial cells

N Maleki,Gh Parnian,S Heyati,F Karami,M Hadizadeh,Appletree Medical Group, 275 Dundad W (Grange), Toronto, Ontario, Canada; ,Gynecology And Reproductive Biology Department, Kowsar Poly-Clinic, Tehran, Iran; ,

doi:10.15407/ubj93.04.037

Abstract

miR-329-containing exosomes derived from breast tumor cells suppress VEGF and KDM1A expression in endothelial cells

Highlights

The exosomal transfer of miRNAs from tumor cells is considered to modulate Vascular Endothelial Growth Factor (VEGF) expression and angiogenesis in endothelial cells
Since exosomes are a rich and protected source of microRNAs, it is presumed that the exosomal transfer of miRNAs from tumor cells to endothelial cells may be a factor in modulating VEGF expression and regulating angiogenesis
Considering the biological functions of exo somes, we initially evaluated whether tumor exo somes carrying microRNAs can per se regulate VEGF-related angiogenesis in vascular endothelial cells, and subsequently, we sought to determine whether tamoxifen could change the breast cancer angio-miR-329 level in breast cancer cell line MCF-7 to represent potential use of tamoxifen for develo ping new therapeutic strategies in breast cancer patients

Summary

Introduction

The exosomal transfer of miRNAs from tumor cells is considered to modulate VEGF expression and angiogenesis in endothelial cells. Since exosomes are a rich and protected source of microRNAs, it is presumed that the exosomal transfer of miRNAs from tumor cells to endothelial cells may be a factor in modulating VEGF expression and regulating angiogenesis. This provides the feasibility of using these regulatory non-coding, endogenous, evolutionarily-conserved RNAs as adjuvant therapy with anti-cancer treatments to enhance therapeutic efficacy [11]. Considering the biological functions of exo somes, we initially evaluated whether tumor exo somes carrying microRNAs can per se regulate VEGF-related angiogenesis in vascular endothelial cells, and subsequently, we sought to determine whether tamoxifen could change the breast cancer angio-miR-329 level in breast cancer cell line MCF-7 to represent potential use of tamoxifen for develo ping new therapeutic strategies in breast cancer patients

Methods

Results

Discussion

Conclusion